TOKYO, Oct 2, 2024 – (JCN Newswire) – – Eisai Co (OTC:)., Ltd. introduced immediately that fully-fledged operations and enterprise actions have begun at Eisai Prescribed drugs Single Particular person Restricted Legal responsibility Firm (Eisai Saudi Arabia), a pharmaceutical gross sales subsidiary not too long ago established in Riyadh within the Kingdom of Saudi Arabia (Saudi Arabia). Eisai Saudi Arabia is a wholly-owned subsidiary of Eisai’s European regional headquarters, Eisai Europe Ltd. (Location: U.Okay.).
Within the Sixties, Eisai began enterprise within the Center East advertising and promoting Eisai merchandise throughlocal distribution companions. In Saudi Arabia, Eisai started promoting the peripheral neuropathy treatmentMethycobal in 2009, and has since expanded the product pipeline with the launch of antiepileptic drug Fycompa in 2018, anticancer drug Lenvima in 2020, and others, by means of native distribution companions. Eisai Saudi Arabia was established in April 2024 in an effort to construct an in-house gross sales system in Saudi Arabia, and is within the technique of taking up industrial rights for the Eisai merchandise in Saudi Arabia from native distribution companions. Eisai Saudi Arabia began gross sales and advertising actions for Methycobaland Fycompa in October 2024, and plans to broaden actions to incorporate Lenvima and anticancer agent Halaven from April 2025. Furthermore, an software for Alzheimer’s illness remedy lecanemab(generic title, international model title: Leqembi) has been submitted for evaluation in Saudi Arabia.
Saudi Arabia’s pharmaceutical market reached 11,342 million USD in 2023, making it the most important market within the Center East, with a mean progress price of seven% in native foreign money phrases from 2019 to 2023.1With the graduation of operations at Eisai Saudi Arabia, Eisai goals to make the most of its personal drug salessystem in Saudi Arabia, ship modern new medicine to extra sufferers within the nation as shortly aspossible, and contribute to enhancing the advantages of sufferers and their households.
1. Define of Eisai Saudi Arabia
1) Firm Identify: Eisai Prescribed drugs Single Particular person Restricted Legal responsibility Firm
2) Location: Riyadh, Kingdom of Saudi Arabia
3) Scope of Enterprise: Import and advertising of pharmaceutical merchandise
4) Constitution Capital: 32,800,000 Saudi Riyal (roughly 1.25 billion JPY)
5) Shareholder: Eisai Europe Ltd.
6) Date of Institution: April 2, 2024
Concerning the Pharmaceutical Market in Saudi Arabia
Saudi Arabia has a inhabitants of about 35 million and a GDP per capita of 118,216 Saudi riyals (approx. 31,445 USD). Saudi Arabia additionally has the most important pharmaceutical market within the Center East, reaching 11,342 million USD in 2023 with a mean progress price of seven% in native foreign money phrases from 2019 to 2023.(1)
The healthcare market in Saudi Arabia consists of two main segments, the general public sector and personal sector.The general public sector is absolutely funded by the federal government, and gives all public sector workers and their households, in addition to Saudi Arabia residents with out medical health insurance, with entry to medical care totally free at authorities amenities.2 Within the non-public sector, firms are required to supply medical health insurance for his or her employeesand bills are depending on the insurance coverage coverage.(2)
In 2016, Saudi Arabia introduced Imaginative and prescient 2030, an financial reform idea towards 2030 with the purpose to shift Saudi Arabia to an economic system that does not depend on oil. In response to Imaginative and prescient 2030, the Ministry of Well being of Saudi Arabia goals to construct a simpler and complete medical system, increasing well being providers and medical amenities and digitalization.
(1) Created primarily based on IQVIA World Evaluate Analyst 2024, Information Interval 2019-2023 (Copyright 2024 IQVIA.). Reprinted with permission.
(2) Ministry of Financial system, Commerce and Trade, Medical and Worldwide Growth Nation Report: Saudi Arabia https://tinyurl.com/rwn8883c
Media Inquiries:
Public Relations Division
Eisai Co., Ltd.
+81-(0)3-3817-5120
Copyright 2024 JCN Newswire . All rights reserved.
